While an increasing number of options are available or in development for effectively treating patients with HCV infection, many clinicians find it challenging to keep abreast of important developments in HCV therapeutics. This 1.5-hour Internet symposium will review and discuss the key studies on chronic hepatitis C presented at the 49th Annual Meeting of the European Association for the Study of the Liver (49th EASL).
The expected result is that participants will not only gain an increased understanding of key data presented at the 49th EASL, they will also be better prepared to address their HCV patients' health needs and provide optimal care, which should improve adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc.. It is not a session created by or presented at the 49th EASL and it is not sanctioned by the 49th EASL.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at the 49th EASL
Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at the 49th EASL, to improve patient care
Engage patients and colleagues in discussion on studies and data presented at the 49th EASL relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC
Release Date: April 23, 2014
Expiration Date: April 23, 2015
Estimated time to complete the Web Symposium: 1 Hour, 45 Minutes
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas
K. Rajender Reddy, MD
Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring materials for a maximum of 1.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Nezam Afdhal:
Contracted Research: Merck; GSK; Vertex; Gilead; AbbVie; BMS; Janssen
Consulting Fees/Advisory Boards: Merck; Gilead; Echosens; GSK; Vertex; Novartis; BIPI; Ligand; Springbank; Medgenics; Kadmon; Janssen; AbbVie
Stock Options: Spring; Medgenics
Dr. Fred Poordad:
Contracted Research: Salix; Vertex; Schering-Plough; Roche; HGS; Novartis; Valeant; Idenix; Gilead; AbbVie; BMS; Zymogenetics; Onyx; Merck
Consulting Fees/Advisory Boards: Salix; Merck; Genentech; Gilead; Onyx; Abbott; Idenix; Tibotec
Speaker's Bureau: Gilead; Merck; Genentech; Salix; Schering-Plough; Onyx
Dr. K. Rajender Reddy:
Consulting Fees: Merck, Tibotec; Gilead; Vertex; Roche
Contracted Research (To UPenn); BMS; Gilead; Tibotec; Merck; Anadys; Pharmasset
Dr. Mark Sulkowski:
Contracted Research (To JHU): AbbVie; BIPI; BMS; Gilead; Janssen; Merck; Vertex
Consulting Fees: AbbVie, BIPI; BMS; Gilead; Janssen; Idenix; Merck
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP and Jan Shultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planner. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
There are no fees for participating and receiving CME credit for this activity. During the period, April 23, 2014 through April 23, 2015, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 9899. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an unrestricted educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
